Inhibiting of Presenilin‐Like Peptidase SPPL2b Reduces Neuroinflammation, Amyloid Pathology, and Synaptic Loss in Alzheimer's Disease: A Promising Therapeutic Target

Our findings underline the critical role of SPPL2b in the development of Aβ pathology in AD. In a global context where innovative strategies to prevent and mitigate AD progression are urgently needed, this study highlights SPPL2b as a promising therapeutic target. Futhermore, the identified compounds are now undergoing in vitro evaluation and the most promising inhibitors will be tested in vivo to assess their effects on AD pathology.